

Tumor flare pain reaction following bispecific T-cell engagers in multiple myeloma: a unique and underrecognized toxicity

Authors

Gaspard Jadot,¹ Anna Sabouret,¹ Anne Couture,² Louis Laflamme,² Frédéric Larose,³ Imran Ahmad,^{1,4} Karim Benkirane,⁵ Jean-Sébastien Delisle,^{1,4} Isabelle Fleury,¹ Silvy Lachance,¹ Richard LeBlanc,¹ Jean Roy,^{1,4} Stéphanie Thiant,¹ Olivier Veilleux¹ and Jean-Sébastien Claveau^{1,4}

¹Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal; ²Nuclear Medicine Department, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal; ³Division of Hematology, Hôtel-Dieu de Lévis, CISSS de Chaudières-Appalaches, Lévis; ⁴Hôpital Maisonneuve-Rosemont Research Center, University of Montreal, Montreal and

⁵Biochemistry Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Canada

Correspondence:

J-S. CLAVEAU - jean-sebastien.claveau@umontreal.ca

<https://doi.org/10.3324/haematol.2025.289122>

Received: September 7, 2025.

Accepted: March 16, 2026.

Early view: March 26, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Supplemental Table 1 – Characteristics of patients with acute tumor flare pain reaction following treatment with teclistamab

Median age in years (range)	61 (41-79)
Biological male sex - no. (%)	5 (50)
Race - no (%)	
White	9 (90)
Black	1 (10)
≥1 Extramedullary plasmacytoma - no. (%)	9 (90)
High-risk cytogenetic profile - no./total no. (%)	3/9 (33.3)
International Staging System class - no./total no. (%)	
ISS 1	4/9 (44.4)
ISS 2	3/9 (33.3)
ISS 3	2/9 (22.2)
Revised International Staging System (R-ISS) class - no./total no. (%)	
R-ISS 1	1/7 (14.3)
R-ISS 2	5/7 (71.4)
R-ISS 3	1/7 (14.3)
Renal clearance ≤30mL/min - no. (%)	0 (0)
Median time since diagnosis - years (range)	2.2 (0.6-9.2)
Median no. of previous lines of therapy (range)	3 (2-5)
Triple class exposure - no. (%)	10 (100)
Prophylactic use of tocilizumab - no. (%)	10 (100)